Citius Pharmaceuticals, Inc. (CTXR)Healthcare | Biotechnology | Cranford, United States | NasdaqCM
0.60 USD
-0.01
(-1.954%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 0.60 |
Hot Take ↕ | Aug. 22, 2026, 2:56 a.m. EDT
The long-term investment case is effectively zero due to a catastrophic multi-year decline where the stock has lost 99.4% of its value over nine years, with four consecutive years of negative returns ending recently. The business is bleeding cash, posting massive losses, and trading at a fraction of its book value, which reflects a market verdict that the current operations are not sustainable without a miracle turnaround. While the short-term chart shows some recent volatility and a slight uptick, the underlying fundamentals are broken, making any rally highly suspect. The options market confirms this desperation, with traders buying deep out-of-the-money calls as a gamble for a sudden re-rating rather than investing in the company's actual performance. This is a high-risk speculative vehicle, not an investment. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.088512 |
| MSTL | 0.098981 |
| AutoARIMA | 0.125990 |
| AutoETS | 0.129247 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 24% |
| H-stat | 7.03 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.002 |
| Excess Kurtosis | 1.14 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 9.455 |
| Revenue per Share | 0.326 |
| Market Cap | 16,529,193 |
| Forward P/E | -0.42 |
| Beta | 0.99 |
| Website | https://citiuspharma.com |
As of Aug. 22, 2026, 2:56 a.m. EDT: Speculator positioning is overwhelmingly skewed toward out-of-the-money calls, with significant open interest concentrated at strikes far above the current price (e.g., 2.5x and 7.5x). This indicates a speculative 'lottery ticket' mentality rather than a hedge against downside risk. Put volume is negligible compared to call volume, suggesting traders are ignoring the severe fundamental deterioration in favor of a binary recovery thesis.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.51240313 |
| Address1 | 11 Commerce Drive |
| Address2 | First Floor |
| All Time High | 937.5 |
| All Time Low | 0.469 |
| Ask | 0.7798 |
| Ask Size | 2 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 1,033,930 |
| Average Daily Volume3 Month | 564,519 |
| Average Volume | 564,519 |
| Average Volume10Days | 1,033,930 |
| Beta | 0.994 |
| Bid | 0.4394 |
| Bid Size | 2 |
| Book Value | 2.426 |
| City | Cranford |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.6021 |
| Current Ratio | 0.839 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 0.6276 |
| Day Low | 0.59 |
| Debt To Equity | 9.455 |
| Display Name | Citius Pharmaceuticals |
| Dividend Date | 1,496,966,400 |
| Earnings Timestamp End | 1,786,737,600 |
| Earnings Timestamp Start | 1,786,737,600 |
| Ebitda Margins | 0.0 |
| Enterprise To Revenue | 2.251 |
| Enterprise Value | 15,994,111 |
| Eps Current Year | -2.03 |
| Eps Forward | -1.44 |
| Eps Trailing Twelve Months | -1.67 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 0.59 |
| Fifty Day Average Change | 0.012100041 |
| Fifty Day Average Change Percent | 0.020508545 |
| Fifty Two Week Change Percent | -51.240314 |
| Fifty Two Week High | 2.19 |
| Fifty Two Week High Change | -1.5879 |
| Fifty Two Week High Change Percent | -0.7250685 |
| Fifty Two Week Low | 0.469 |
| Fifty Two Week Low Change | 0.1331 |
| Fifty Two Week Low Change Percent | 0.2837953 |
| Fifty Two Week Range | 0.469 - 2.19 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,412,256,600,000 |
| Float Shares | 26,959,796 |
| Forward Eps | -1.44 |
| Forward P E | -0.418125 |
| Free Cashflow | -36,803,784 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 23 |
| Fullday Change | -0.012 |
| Fullday Change Percent | -1.95407 |
| Fullday Price | 0.6021 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.77342004 |
| Gross Profits | 5,495,268 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01795 |
| Held Percent Institutions | 0.04956 |
| Implied Shares Outstanding | 27,452,570 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,759,190,400 |
| Last Split Date | 1,732,579,200 |
| Last Split Factor | 1:25 |
| Long Business Summary | Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections; Halo-Lido, a corticosteroid-lidocaine topical formulation to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of ARDS. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey. |
| Long Name | Citius Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 16,529,193 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_272471835 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -46,274,056 |
| Next Fiscal Year End | 1,790,726,400 |
| Non Diluted Market Cap | 17,267,666 |
| Number Of Analyst Opinions | 1 |
| Open | 0.6143 |
| Operating Cashflow | -34,867,204 |
| Operating Margins | -6.70226 |
| Payout Ratio | 0.0 |
| Phone | 908 967 6677 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 0.6021 |
| Post Market Time | 1,787,960,977 |
| Previous Close | 0.6141 |
| Price Eps Current Year | -0.296601 |
| Price Hint | 4 |
| Price To Book | 0.2481863 |
| Price To Sales Trailing12 Months | 2.3263526 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.343 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | -0.012 |
| Regular Market Change Percent | -1.95407 |
| Regular Market Day High | 0.6276 |
| Regular Market Day Low | 0.59 |
| Regular Market Day Range | 0.59 - 0.6276 |
| Regular Market Open | 0.6143 |
| Regular Market Previous Close | 0.6141 |
| Regular Market Price | 0.6021 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 360,730 |
| Return On Assets | -0.26567 |
| Return On Equity | -0.81086 |
| Revenue Per Share | 0.326 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 27,452,570 |
| Shares Percent Shares Out | 0.19549999 |
| Shares Short | 5,366,929 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 4,981,669 |
| Short Name | Citius Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.1991 |
| Short Ratio | 7.16 |
| Source Interval | 15 |
| State | NJ |
| Symbol | CTXR |
| Target High Price | 4.0 |
| Target Low Price | 4.0 |
| Target Mean Price | 4.0 |
| Target Median Price | 4.0 |
| Total Cash | 17,007,524 |
| Total Cash Per Share | 0.62 |
| Total Debt | 7,177,118 |
| Total Revenue | 7,105,197 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.67 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 0.775105 |
| Two Hundred Day Average Change | -0.17300498 |
| Two Hundred Day Average Change Percent | -0.223202 |
| Type Disp | Equity |
| Volume | 360,730 |
| Website | https://citiuspharma.com |
| Zip | 7,016 |